

John H Rex

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8743974/publications.pdf>

Version: 2024-02-01

14
papers

1,789
citations

840585

11
h-index

1125617

13
g-index

14
all docs

14
docs citations

14
times ranked

2673
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010–2020. <i>Clinical Infectious Diseases</i> , 2022, 74, 1183-1190.	2.9	15
2	Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0199121.	1.4	103
3	Antibacterial R&D at a Crossroads: We’ve Pushed as Hard as We Can Now We Need to Start Pulling!. <i>Clinical Infectious Diseases</i> , 2021, 73, e4451-e4453.	2.9	11
4	Antibiotic development – economic, regulatory and societal challenges. <i>Nature Reviews Microbiology</i> , 2020, 18, 267-274.	13.6	218
5	Critical analysis of antibacterial agents in clinical development. <i>Nature Reviews Microbiology</i> , 2020, 18, 286-298.	13.6	204
6	Designing development programs for non-traditional antibacterial agents. <i>Nature Communications</i> , 2019, 10, 3416.	5.8	46
7	Analysis of the clinical antibacterial and antituberculosis pipeline. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e40-e50.	4.6	161
8	Progress in the Fight Against Multidrug-Resistant Bacteria 2005–2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance. <i>Clinical Infectious Diseases</i> , 2017, 65, 141-146.	2.9	56
9	Efficient Delivery of Investigational Antibacterial Agents via Sustainable Clinical Trial Networks. <i>Clinical Infectious Diseases</i> , 2016, 63, S57-S59.	2.9	28
10	Alternatives to antibiotics – a pipeline portfolio review. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 239-251.	4.6	720
11	Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 500-505.	4.6	86
12	The evolution of the regulatory framework for antibacterial agents. <i>Annals of the New York Academy of Sciences</i> , 2014, 1323, 11-21.	1.8	30
13	Addressing the need for new antibacterials – Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 834-835.	4.6	0
14	A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 269-275.	4.6	111